Concepts (280)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Xylans | 18 | 2024 | 23 | 8.620 |
Why?
|
| Apoptosis | 24 | 2022 | 1398 | 5.130 |
Why?
|
| Carcinoma, Ehrlich Tumor | 7 | 2020 | 19 | 3.580 |
Why?
|
| Saccharomyces cerevisiae | 9 | 2019 | 206 | 2.670 |
Why?
|
| Dendritic Cells | 6 | 2019 | 113 | 2.480 |
Why?
|
| Antioxidants | 8 | 2024 | 416 | 2.440 |
Why?
|
| Probiotics | 4 | 2020 | 25 | 2.180 |
Why?
|
| Breast Neoplasms | 13 | 2022 | 1502 | 2.100 |
Why?
|
| Oxidative Stress | 10 | 2024 | 938 | 2.080 |
Why?
|
| Radiation Injuries | 3 | 2024 | 22 | 1.830 |
Why?
|
| Paclitaxel | 4 | 2019 | 50 | 1.760 |
Why?
|
| Lactobacillus | 3 | 2020 | 15 | 1.760 |
Why?
|
| Liver | 4 | 2022 | 479 | 1.460 |
Why?
|
| Animals | 33 | 2024 | 15081 | 1.410 |
Why?
|
| Streptozocin | 4 | 2022 | 21 | 1.380 |
Why?
|
| CD4-Positive T-Lymphocytes | 6 | 2019 | 259 | 1.370 |
Why?
|
| Stomach Neoplasms | 3 | 2016 | 195 | 1.360 |
Why?
|
| Alzheimer Disease | 3 | 2021 | 905 | 1.360 |
Why?
|
| Antineoplastic Agents | 6 | 2020 | 803 | 1.360 |
Why?
|
| Iron | 4 | 2024 | 225 | 1.360 |
Why?
|
| Mice | 21 | 2024 | 5913 | 1.320 |
Why?
|
| Cell Line, Tumor | 21 | 2022 | 2231 | 1.280 |
Why?
|
| Anti-Inflammatory Agents | 2 | 2021 | 149 | 1.270 |
Why?
|
| CD8-Positive T-Lymphocytes | 4 | 2018 | 159 | 1.220 |
Why?
|
| Cytokines | 10 | 2024 | 602 | 1.210 |
Why?
|
| Flow Cytometry | 14 | 2021 | 399 | 1.200 |
Why?
|
| Diabetes Mellitus, Experimental | 3 | 2024 | 94 | 1.190 |
Why?
|
| Aging | 4 | 2020 | 664 | 1.180 |
Why?
|
| Radiation-Protective Agents | 3 | 2024 | 14 | 1.170 |
Why?
|
| Cell Proliferation | 9 | 2022 | 1198 | 1.150 |
Why?
|
| bcl-2-Associated X Protein | 7 | 2021 | 77 | 1.100 |
Why?
|
| Trifolium | 2 | 2024 | 2 | 1.080 |
Why?
|
| Platinum | 3 | 2017 | 19 | 1.040 |
Why?
|
| Thymus Extracts | 3 | 2009 | 5 | 1.030 |
Why?
|
| Iron Compounds | 2 | 2019 | 4 | 1.010 |
Why?
|
| Cultured Milk Products | 2 | 2015 | 2 | 1.010 |
Why?
|
| Rats, Wistar | 7 | 2024 | 233 | 0.960 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 8 | 2016 | 152 | 0.950 |
Why?
|
| Minerals | 2 | 2018 | 47 | 0.950 |
Why?
|
| Adenocarcinoma | 3 | 2019 | 251 | 0.900 |
Why?
|
| Killer Cells, Natural | 6 | 2021 | 92 | 0.900 |
Why?
|
| Spleen | 4 | 2019 | 199 | 0.890 |
Why?
|
| Hematologic Diseases | 2 | 2013 | 14 | 0.880 |
Why?
|
| Lymphocyte Activation | 5 | 2018 | 236 | 0.880 |
Why?
|
| Phagocytosis | 8 | 2008 | 69 | 0.840 |
Why?
|
| Dietary Supplements | 2 | 2021 | 208 | 0.820 |
Why?
|
| Immunoglobulin A, Secretory | 1 | 2021 | 16 | 0.810 |
Why?
|
| Placental Extracts | 1 | 2021 | 3 | 0.810 |
Why?
|
| Methotrexate | 1 | 2021 | 23 | 0.800 |
Why?
|
| Respiratory Tract Infections | 1 | 2021 | 33 | 0.800 |
Why?
|
| Fermentation | 1 | 2021 | 26 | 0.790 |
Why?
|
| Immunity, Mucosal | 1 | 2021 | 47 | 0.790 |
Why?
|
| DNA Damage | 6 | 2020 | 352 | 0.780 |
Why?
|
| Immunosuppressive Agents | 1 | 2021 | 76 | 0.770 |
Why?
|
| Anti-Infective Agents | 1 | 2021 | 64 | 0.770 |
Why?
|
| Placenta | 1 | 2021 | 97 | 0.760 |
Why?
|
| Cognition | 2 | 2021 | 398 | 0.760 |
Why?
|
| Immunity, Innate | 1 | 2021 | 149 | 0.750 |
Why?
|
| Intestinal Mucosa | 1 | 2021 | 122 | 0.750 |
Why?
|
| Coated Materials, Biocompatible | 2 | 2010 | 19 | 0.730 |
Why?
|
| Immunomodulation | 1 | 2020 | 15 | 0.730 |
Why?
|
| Liver Neoplasms, Experimental | 1 | 2020 | 23 | 0.720 |
Why?
|
| Female | 23 | 2022 | 20969 | 0.720 |
Why?
|
| Antiviral Agents | 2 | 2023 | 157 | 0.710 |
Why?
|
| Seawater | 2 | 2018 | 45 | 0.690 |
Why?
|
| Whole-Body Irradiation | 2 | 2024 | 9 | 0.680 |
Why?
|
| Mammary Neoplasms, Animal | 1 | 2019 | 30 | 0.670 |
Why?
|
| Humans | 31 | 2024 | 37093 | 0.660 |
Why?
|
| Biological Products | 1 | 2020 | 71 | 0.660 |
Why?
|
| Leukocytes, Mononuclear | 3 | 2024 | 234 | 0.640 |
Why?
|
| Neuroprotective Agents | 1 | 2021 | 245 | 0.630 |
Why?
|
| Paracrine Communication | 1 | 2018 | 15 | 0.620 |
Why?
|
| Membrane Potential, Mitochondrial | 5 | 2022 | 84 | 0.610 |
Why?
|
| Antineoplastic Agents, Phytogenic | 2 | 2016 | 110 | 0.600 |
Why?
|
| Cells, Cultured | 7 | 2019 | 1518 | 0.590 |
Why?
|
| Adjuvants, Immunologic | 1 | 2018 | 107 | 0.580 |
Why?
|
| Glutathione | 5 | 2024 | 179 | 0.580 |
Why?
|
| Bacterial Proteins | 1 | 2021 | 540 | 0.580 |
Why?
|
| Viremia | 1 | 2016 | 42 | 0.560 |
Why?
|
| Radiation Tolerance | 2 | 2013 | 12 | 0.560 |
Why?
|
| Keratinocytes | 1 | 2017 | 66 | 0.560 |
Why?
|
| Hepatitis C, Chronic | 1 | 2016 | 39 | 0.550 |
Why?
|
| Male | 15 | 2024 | 20025 | 0.550 |
Why?
|
| Stomach | 1 | 2016 | 45 | 0.540 |
Why?
|
| Lipid Peroxidation | 4 | 2021 | 140 | 0.530 |
Why?
|
| Brain | 2 | 2021 | 1346 | 0.520 |
Why?
|
| Disease Models, Animal | 4 | 2021 | 1371 | 0.520 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2014 | 222 | 0.510 |
Why?
|
| Protective Agents | 1 | 2015 | 25 | 0.500 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2022 | 643 | 0.480 |
Why?
|
| Leukemia, Myeloid | 1 | 2014 | 9 | 0.480 |
Why?
|
| Tumor Burden | 3 | 2019 | 77 | 0.480 |
Why?
|
| Rats | 7 | 2024 | 3483 | 0.480 |
Why?
|
| Cell Cycle | 3 | 2020 | 326 | 0.470 |
Why?
|
| Malondialdehyde | 3 | 2021 | 41 | 0.470 |
Why?
|
| Gamma Rays | 3 | 2024 | 26 | 0.460 |
Why?
|
| Esophageal Neoplasms | 1 | 2015 | 127 | 0.450 |
Why?
|
| Hematopoietic System | 1 | 2013 | 3 | 0.440 |
Why?
|
| Quercetin | 2 | 2024 | 45 | 0.430 |
Why?
|
| Mitochondria | 4 | 2015 | 487 | 0.430 |
Why?
|
| Caspase 3 | 3 | 2021 | 207 | 0.420 |
Why?
|
| Candida albicans | 2 | 2004 | 164 | 0.400 |
Why?
|
| Antigens, CD | 4 | 2015 | 121 | 0.380 |
Why?
|
| Lymphocytes | 2 | 2009 | 118 | 0.380 |
Why?
|
| Dose-Response Relationship, Drug | 6 | 2013 | 1039 | 0.380 |
Why?
|
| T-Lymphocytes | 2 | 2010 | 357 | 0.370 |
Why?
|
| Nanofibers | 1 | 2010 | 12 | 0.360 |
Why?
|
| Immune System Diseases | 1 | 2010 | 21 | 0.360 |
Why?
|
| Aged | 4 | 2024 | 6741 | 0.330 |
Why?
|
| Calcium | 2 | 2009 | 480 | 0.330 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2010 | 145 | 0.320 |
Why?
|
| Daunorubicin | 1 | 2008 | 3 | 0.320 |
Why?
|
| Liver Neoplasms | 1 | 2010 | 190 | 0.310 |
Why?
|
| Inflammation | 3 | 2024 | 618 | 0.310 |
Why?
|
| Combined Modality Therapy | 2 | 2019 | 148 | 0.310 |
Why?
|
| Metal Nanoparticles | 1 | 2010 | 183 | 0.300 |
Why?
|
| Yeast, Dried | 1 | 2007 | 1 | 0.300 |
Why?
|
| Body Weight | 3 | 2019 | 434 | 0.300 |
Why?
|
| Organ Size | 2 | 2019 | 157 | 0.290 |
Why?
|
| Lysosomal-Associated Membrane Protein 1 | 2 | 2018 | 3 | 0.290 |
Why?
|
| Signal Transduction | 4 | 2024 | 1908 | 0.290 |
Why?
|
| Double-Blind Method | 2 | 2021 | 286 | 0.280 |
Why?
|
| Interferon-gamma | 3 | 2016 | 250 | 0.280 |
Why?
|
| Methylnitronitrosoguanidine | 2 | 2016 | 6 | 0.270 |
Why?
|
| Coculture Techniques | 3 | 2018 | 101 | 0.270 |
Why?
|
| Plant Extracts | 3 | 2024 | 286 | 0.260 |
Why?
|
| Tongue Neoplasms | 1 | 2005 | 11 | 0.260 |
Why?
|
| Fungi | 1 | 2006 | 89 | 0.250 |
Why?
|
| Middle Aged | 4 | 2024 | 10129 | 0.250 |
Why?
|
| Immunologic Factors | 1 | 2004 | 45 | 0.240 |
Why?
|
| Testicular Diseases | 1 | 2024 | 1 | 0.240 |
Why?
|
| Portulaca | 1 | 2024 | 3 | 0.240 |
Why?
|
| Enzyme Activation | 4 | 2008 | 444 | 0.240 |
Why?
|
| Caspases | 4 | 2005 | 147 | 0.240 |
Why?
|
| Leukemia, T-Cell | 1 | 2003 | 5 | 0.240 |
Why?
|
| Hypoglycemic Agents | 2 | 2024 | 160 | 0.230 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2017 | 37 | 0.230 |
Why?
|
| Mice, Inbred C57BL | 4 | 2010 | 1609 | 0.230 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2005 | 178 | 0.220 |
Why?
|
| Papain | 1 | 2023 | 5 | 0.220 |
Why?
|
| Peptide Hydrolases | 1 | 2023 | 40 | 0.220 |
Why?
|
| Vero Cells | 1 | 2023 | 93 | 0.220 |
Why?
|
| Colonic Neoplasms | 1 | 2005 | 186 | 0.220 |
Why?
|
| Neoplasm Invasiveness | 1 | 2004 | 251 | 0.220 |
Why?
|
| Blotting, Western | 3 | 2009 | 859 | 0.210 |
Why?
|
| Hesperidin | 1 | 2022 | 5 | 0.210 |
Why?
|
| Glucose Transport Proteins, Facilitative | 1 | 2022 | 14 | 0.210 |
Why?
|
| Carbohydrate Metabolism | 1 | 2022 | 21 | 0.210 |
Why?
|
| Receptor, Insulin | 1 | 2022 | 25 | 0.210 |
Why?
|
| Cerebral Cortex | 1 | 2024 | 290 | 0.210 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2024 | 269 | 0.210 |
Why?
|
| Insulin Resistance | 1 | 2024 | 184 | 0.210 |
Why?
|
| Egypt | 1 | 2021 | 6 | 0.210 |
Why?
|
| Receptors, Retinoic Acid | 1 | 2021 | 26 | 0.200 |
Why?
|
| Intestine, Small | 1 | 2021 | 25 | 0.200 |
Why?
|
| Ovalbumin | 1 | 2021 | 47 | 0.200 |
Why?
|
| Liver Function Tests | 1 | 2021 | 18 | 0.200 |
Why?
|
| Aspartate Aminotransferases | 1 | 2021 | 19 | 0.200 |
Why?
|
| Ubiquitins | 1 | 2021 | 46 | 0.200 |
Why?
|
| Cholera Toxin | 1 | 2021 | 39 | 0.200 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2022 | 58 | 0.200 |
Why?
|
| Alanine Transaminase | 1 | 2021 | 30 | 0.200 |
Why?
|
| Seasons | 1 | 2021 | 112 | 0.200 |
Why?
|
| Cell Line | 2 | 2021 | 1354 | 0.190 |
Why?
|
| Oxidation-Reduction | 2 | 2015 | 431 | 0.190 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 2 | 2010 | 18 | 0.190 |
Why?
|
| Diethylnitrosamine | 1 | 2020 | 1 | 0.180 |
Why?
|
| Janus Kinase 2 | 1 | 2020 | 32 | 0.180 |
Why?
|
| Cell Survival | 2 | 2017 | 864 | 0.180 |
Why?
|
| Chemoprevention | 1 | 2020 | 35 | 0.180 |
Why?
|
| tau Proteins | 1 | 2021 | 167 | 0.180 |
Why?
|
| Seeds | 1 | 2020 | 35 | 0.180 |
Why?
|
| Prostatic Neoplasms | 1 | 2009 | 935 | 0.180 |
Why?
|
| Maze Learning | 1 | 2020 | 105 | 0.180 |
Why?
|
| Insulin | 1 | 2022 | 236 | 0.180 |
Why?
|
| X-Rays | 1 | 2019 | 18 | 0.180 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2021 | 77 | 0.180 |
Why?
|
| Mice, Inbred BALB C | 1 | 2021 | 661 | 0.180 |
Why?
|
| DNA Fragmentation | 1 | 2019 | 92 | 0.170 |
Why?
|
| Nanoparticles | 1 | 2024 | 318 | 0.170 |
Why?
|
| STAT3 Transcription Factor | 1 | 2020 | 90 | 0.170 |
Why?
|
| Autophagy | 1 | 2020 | 116 | 0.170 |
Why?
|
| Down-Regulation | 2 | 2016 | 435 | 0.170 |
Why?
|
| Pilot Projects | 1 | 2021 | 661 | 0.170 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2015 | 807 | 0.170 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2020 | 147 | 0.170 |
Why?
|
| Up-Regulation | 1 | 2021 | 513 | 0.170 |
Why?
|
| Treatment Outcome | 2 | 2013 | 1369 | 0.160 |
Why?
|
| Incidence | 1 | 2021 | 922 | 0.160 |
Why?
|
| Behavior, Animal | 1 | 2021 | 314 | 0.160 |
Why?
|
| Lung | 1 | 2021 | 446 | 0.160 |
Why?
|
| Epithelial Cells | 1 | 2021 | 384 | 0.160 |
Why?
|
| HLA-DR Antigens | 1 | 2018 | 21 | 0.160 |
Why?
|
| Crystallization | 1 | 2018 | 86 | 0.150 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2019 | 213 | 0.150 |
Why?
|
| Amino Acid Chloromethyl Ketones | 2 | 2008 | 8 | 0.150 |
Why?
|
| Nerve Growth Factor | 1 | 2017 | 30 | 0.140 |
Why?
|
| Ribavirin | 1 | 2016 | 18 | 0.140 |
Why?
|
| TRPV Cation Channels | 1 | 2017 | 24 | 0.140 |
Why?
|
| Drug Agonism | 1 | 2016 | 1 | 0.140 |
Why?
|
| Hippocampus | 1 | 2020 | 561 | 0.140 |
Why?
|
| Reactive Oxygen Species | 2 | 2010 | 461 | 0.140 |
Why?
|
| Age Factors | 1 | 2020 | 1033 | 0.140 |
Why?
|
| Drug Synergism | 2 | 2008 | 177 | 0.140 |
Why?
|
| Gastric Mucosa | 1 | 2016 | 51 | 0.140 |
Why?
|
| Pregnancy | 1 | 2021 | 1549 | 0.140 |
Why?
|
| Drug Therapy, Combination | 1 | 2016 | 227 | 0.140 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2016 | 146 | 0.130 |
Why?
|
| Integrin alpha Chains | 1 | 2015 | 3 | 0.130 |
Why?
|
| Cost-Benefit Analysis | 1 | 2016 | 144 | 0.130 |
Why?
|
| Viral Load | 1 | 2016 | 312 | 0.130 |
Why?
|
| Free Radicals | 1 | 2015 | 74 | 0.130 |
Why?
|
| Gene Expression Regulation | 1 | 2019 | 1015 | 0.120 |
Why?
|
| HL-60 Cells | 1 | 2014 | 32 | 0.120 |
Why?
|
| Drug Resistance, Multiple | 1 | 2014 | 27 | 0.120 |
Why?
|
| Cichlids | 1 | 2013 | 4 | 0.110 |
Why?
|
| Membrane Potentials | 2 | 2004 | 223 | 0.110 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2013 | 36 | 0.110 |
Why?
|
| Radiation Dosage | 1 | 2013 | 37 | 0.110 |
Why?
|
| Tumor Cells, Cultured | 1 | 2014 | 502 | 0.110 |
Why?
|
| Diet | 1 | 2019 | 801 | 0.110 |
Why?
|
| Survival Rate | 1 | 2013 | 311 | 0.100 |
Why?
|
| California | 1 | 2013 | 476 | 0.100 |
Why?
|
| Ethiodized Oil | 1 | 2010 | 3 | 0.100 |
Why?
|
| Chemoembolization, Therapeutic | 1 | 2010 | 5 | 0.100 |
Why?
|
| Administration, Cutaneous | 1 | 2010 | 43 | 0.090 |
Why?
|
| alpha-Fetoproteins | 1 | 2010 | 31 | 0.090 |
Why?
|
| Catheter Ablation | 1 | 2010 | 30 | 0.090 |
Why?
|
| Thyrotropin | 1 | 2010 | 17 | 0.090 |
Why?
|
| Diamond | 1 | 2010 | 5 | 0.090 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 1 | 2010 | 10 | 0.090 |
Why?
|
| Doxorubicin | 1 | 2010 | 84 | 0.090 |
Why?
|
| Housing, Animal | 1 | 2010 | 11 | 0.090 |
Why?
|
| Lectins, C-Type | 1 | 2010 | 36 | 0.090 |
Why?
|
| Neoplasm Staging | 1 | 2010 | 275 | 0.090 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 2009 | 24 | 0.090 |
Why?
|
| Administration, Oral | 1 | 2010 | 224 | 0.090 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2010 | 128 | 0.090 |
Why?
|
| Trypan Blue | 1 | 2009 | 2 | 0.090 |
Why?
|
| Drinking | 1 | 2009 | 38 | 0.090 |
Why?
|
| Cell Shape | 1 | 2009 | 35 | 0.090 |
Why?
|
| Cell Count | 1 | 2009 | 135 | 0.090 |
Why?
|
| Weight Gain | 1 | 2010 | 136 | 0.080 |
Why?
|
| Ethanol | 1 | 2010 | 192 | 0.080 |
Why?
|
| Beverages | 1 | 2009 | 68 | 0.080 |
Why?
|
| B-Lymphocytes | 1 | 2009 | 185 | 0.080 |
Why?
|
| Caspase 9 | 1 | 2008 | 30 | 0.080 |
Why?
|
| Prevalence | 1 | 2013 | 1455 | 0.080 |
Why?
|
| Monocytes | 1 | 2010 | 257 | 0.080 |
Why?
|
| Caspase 8 | 1 | 2008 | 32 | 0.080 |
Why?
|
| Adult | 2 | 2016 | 11712 | 0.080 |
Why?
|
| Hydrogen Peroxide | 1 | 2009 | 190 | 0.080 |
Why?
|
| Cytoplasm | 1 | 2008 | 143 | 0.080 |
Why?
|
| Lipopolysaccharides | 1 | 2009 | 220 | 0.080 |
Why?
|
| Injections, Intraperitoneal | 1 | 2008 | 60 | 0.080 |
Why?
|
| Random Allocation | 1 | 2008 | 139 | 0.080 |
Why?
|
| Transplantation, Heterologous | 1 | 2007 | 90 | 0.070 |
Why?
|
| Phenotype | 1 | 2009 | 689 | 0.070 |
Why?
|
| Nitric Oxide | 1 | 2009 | 316 | 0.070 |
Why?
|
| Mycelium | 1 | 2006 | 5 | 0.070 |
Why?
|
| Mice, Nude | 1 | 2007 | 337 | 0.070 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2008 | 356 | 0.070 |
Why?
|
| U937 Cells | 1 | 2005 | 27 | 0.060 |
Why?
|
| Caco-2 Cells | 1 | 2005 | 52 | 0.060 |
Why?
|
| Mice, Inbred C3H | 1 | 2004 | 84 | 0.060 |
Why?
|
| Risk Factors | 1 | 2013 | 3562 | 0.060 |
Why?
|
| Aged, 80 and over | 1 | 2010 | 2379 | 0.060 |
Why?
|
| Plants, Edible | 1 | 2024 | 3 | 0.060 |
Why?
|
| Isoenzymes | 1 | 2005 | 161 | 0.060 |
Why?
|
| Intracellular Membranes | 1 | 2004 | 38 | 0.060 |
Why?
|
| Respiratory Burst | 1 | 2004 | 4 | 0.060 |
Why?
|
| K562 Cells | 1 | 2003 | 32 | 0.060 |
Why?
|
| Acid Phosphatase | 1 | 2003 | 21 | 0.060 |
Why?
|
| Cholesterol | 1 | 2024 | 205 | 0.050 |
Why?
|
| Neoplasm Metastasis | 1 | 2004 | 219 | 0.050 |
Why?
|
| Sensitivity and Specificity | 1 | 2004 | 562 | 0.050 |
Why?
|
| Blood Glucose | 1 | 2024 | 353 | 0.050 |
Why?
|
| Macrophages | 1 | 2005 | 439 | 0.050 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2004 | 1618 | 0.040 |
Why?
|
| Time Factors | 1 | 2003 | 1742 | 0.040 |
Why?
|